Structural biology

Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline

Retrieved on:

星期三, 四月 3, 2024

Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors.

Key Points:

Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors.
The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.
Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways.
Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.

OpenFold Biotech AI Research Consortium releases SoloSeq and Multimer, an integrated protein Large Language Model with 3D structure generation

Retrieved on:

星期一, 二月 19, 2024

OpenFold , a non-profit artificial intelligence (AI) research consortium, today announced the release of two new tools: 1) SoloSeq, which integrates a new protein Large Language Model (LLM) with its OpenFold structure prediction software, and 2) OpenFold-Multimer software, which creates higher quality models of protein/protein complexes than OpenFold alone.

Key Points:

OpenFold , a non-profit artificial intelligence (AI) research consortium, today announced the release of two new tools: 1) SoloSeq, which integrates a new protein Large Language Model (LLM) with its OpenFold structure prediction software, and 2) OpenFold-Multimer software, which creates higher quality models of protein/protein complexes than OpenFold alone.
The new Multimer code is the first fully open source training code system for the generation of protein/protein structures.
View the full release here: https://www.businesswire.com/news/home/20240219658831/en/
OpenFold SoloSeq model prediction vs experimentally resolved structure for PDB protein 4B9Z (Graphic: Business Wire)
“OpenFold-Multimer and SoloSeq are particularly useful for designed proteins that don't exist in nature.
Previous work in protein LLMs, primarily out of Meta AI, has produced a series of valuable LLM standalone models and the ESMFold structure model, which pairs ESM-family LLMs with OpenFold for structure prediction.

UT Health San Antonio secures $16.4 million from CPRIT over six months, adding transformative expertise, bolstering cancer research

Retrieved on:

星期五, 三月 8, 2024

SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) (https://uthscsa.edu/) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas (https://www.cprit.state.tx.us/about-us) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.

Key Points:

SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) ( https://uthscsa.edu/ ) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas ( https://www.cprit.state.tx.us/about-us ) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.
The Mays Cancer Center at UT Health San Antonio ( https://cancer.uthscsa.edu/ ) is one of only four National Cancer Institute-designated Cancer Centers in Texas.
The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.
The Greehey Children's Cancer Research Institute ( https://cancer.uthscsa.edu/gccri ) is one of only two institutes in the United States dedicated solely to pediatric cancer research.

Amide Technologies Announces Complex Peptide Manufacturing Platform, Raises $16.5M to Expedite Frontier Drug Discovery

Retrieved on:

星期四, 十二月 14, 2023

Amide Technologies , a biotech that synthesizes challenging peptides, announced today that it has begun commercializing its novel peptide manufacturing platform.

Key Points:

Amide Technologies , a biotech that synthesizes challenging peptides, announced today that it has begun commercializing its novel peptide manufacturing platform.
New advances in structural biology, recombinant biologics, and AI-driven technologies have improved drug design and delivery methods, overcoming many previous pharmacokinetic behavior drawbacks of peptides .
“Amide delivers on complex peptide orders that other vendors refuse because peptide sourcing shouldn’t stand in the way of discovery,” said Amide CEO Mark Simon, PhD.
ITA Software founder and CEO Jeremy Wertheimer is an Amide co-founder and Board Member, alongside MIT Professor of Chemistry Brad Pentelute, PhD.

TWO BEAR CAPITAL NAMES DR. J. SETH STRATTAN AS GENERAL PARTNER

Retrieved on:

星期二, 九月 19, 2023

MENLO PARK, Calif., Sept. 19, 2023 /PRNewswire/ -- Two Bear Capital, the venture capital firm investing in disruptors in biotechnology, bioinformatics, healthcare IT, machine learning and AI, and information security, today announced the promotion of J. Seth Strattan, PhD to General Partner. In this new leadership role, Dr. Strattan will take on more responsibilities for identifying and securing investment opportunities and mentoring the growth and development of companies within the Two Bear Capital portfolio. He will work closely with Founder and Managing Partner Mike Goguen to chart the strategic course for the firm as it enters a period of expansion. Strattan leads the Silicon Valley office and is focused on the application of data science, software engineering, and genomics technologies to solve problems in medicine and biology.

Key Points:

Leading the Silicon Valley Office, Dr. Strattan's New Role Will Include Expanded Responsibilities for Deal Generation and Mentorship of Companies within the Two Bear Capital Portfolio
MENLO PARK, Calif., Sept. 19, 2023 /PRNewswire/ -- Two Bear Capital, the venture capital firm investing in disruptors in biotechnology, bioinformatics, healthcare IT, machine learning and AI, and information security, today announced the promotion of J. Seth Strattan, PhD to General Partner.
In this new leadership role, Dr. Strattan will take on more responsibilities for identifying and securing investment opportunities and mentoring the growth and development of companies within the Two Bear Capital portfolio.
He will work closely with Founder and Managing Partner Mike Goguen to chart the strategic course for the firm as it enters a period of expansion.
Mike Goguen, Founder and Managing Partner said: "Seth Strattan has been an incredible partner to me and an asset to Two Bear Capital.

Culture Biosciences Appoints Darcy Birse as Chief Commercial Officer

Retrieved on:

星期三, 九月 13, 2023

South San Francisco, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences , a leading provider of innovative, future-forward bioprocessing solutions, is pleased to announce the appointment of Darcy Birse as the company's new Chief Commercial Officer (CCO).

Key Points:

South San Francisco, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences , a leading provider of innovative, future-forward bioprocessing solutions, is pleased to announce the appointment of Darcy Birse as the company's new Chief Commercial Officer (CCO).
Darcy will lead the company's commercial strategy and drive growth initiatives to further strengthen Culture's position as a leader in the bioprocessing industry.
With a career spanning over 30 years in the life sciences sector, Darcy brings a wealth of global experience in Commercial Leadership, Marketing, Sales and Business Development to Culture Biosciences.
"As we continue to expand our presence in the bioprocessing market and deliver novel solutions to our clients, we are thrilled to welcome Darcy Birse to our executive team," said Will Patrick, CEO and Co-founder of Culture Biosciences.

The Inner Circle Acknowledges, Ian A. Wilson as a Distinguished Healthcare Professional for his contributions to the Biomedical Research and Infectious Disease Fields

Retrieved on:

星期二, 九月 5, 2023

JOLLA, Calif., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Ian A. Wilson is acknowledged as a Distinguished Healthcare Professional for his contributions to the Biomedical Research and Infectious Disease Fields.

Key Points:

JOLLA, Calif., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Ian A. Wilson is acknowledged as a Distinguished Healthcare Professional for his contributions to the Biomedical Research and Infectious Disease Fields.
Dr. Wilson pursued higher education at the prestigious University of Edinburgh in Scotland in 1971 where he earned a Bachelor of Science degree in Biochemistry.
In this post, he directed a laboratory involved in biomedical research on infectious diseases.
He currently serves as a Professor at Scripps Research (formerly The Scripps Research Institute or TSRI) in La Jolla, California.

Genesis Therapeutics Closes Oversubscribed $200 Million Series B

Retrieved on:

星期一, 八月 21, 2023

Genesis Therapeutics , a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients with severe diseases, announced today that it has closed an oversubscribed $200 million round of Series B financing.

Key Points:

Genesis Therapeutics , a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients with severe diseases, announced today that it has closed an oversubscribed $200 million round of Series B financing.
Additionally, the Series B capital will enable Genesis to ambitiously expand its pipeline, initiating new programs for underserved patient populations and leveraging the GEMS platform to make progress against challenging and previously undruggable targets.
This funding brings the total capital raised by Genesis Therapeutics to over $280 million.
In addition to the $200 million Series B raise, Genesis further announced that approximately $24 million of SAFE notes from a prior financing round, led by Radical Ventures, converted alongside the close of the Series B. Genesis previously raised a $52 million Series A , led by Rock Springs Capital, and a seed round of $4 million, led by a16z Bio + Health.

Arkifi Emerges from Stealth, Building Factual and Trustworthy Tools with Generative AI for the Finance Industry

Retrieved on:

星期一, 八月 21, 2023

"This is an exciting time to be building a company that will fundamentally change the finance industry," said Hesam Motlagh, co-founder and CEO of Arifki. "With the combined AI expertise of Khosla Ventures and financial experience of Nyca, we are humbled and thrilled to start building out our company." Arkifi's proprietary approach relies on building a technology platform from the ground up with the customer experience in mind, while allowing flexibility in plugging in new models or techniques as they emerge from the rapidly-evolving field of AI. Managing Partner at Nyca Partners, Hans Morris, said, "Nyca believes that AI will be central to the future of banking and investment management, but we also know that financial services firms will only use AI tools that are highly controlled and generate auditable outputs. Arkifi's remarkable workflow automation platform will enhance financial analysts' productivity quite dramatically -- by designing a product with the end-user on Wall Street precisely in mind."

Key Points:

The company has created the world's most powerful finance workflow automation tool using generative AI, and marquee financial institutions are already part of the early access program.
"This is an exciting time to be building a company that will fundamentally change the finance industry," said Hesam Motlagh, co-founder and CEO of Arifki.
"With the combined AI expertise of Khosla Ventures and financial experience of Nyca, we are humbled and thrilled to start building out our company."
Jeremy, on the other hand, spent his years aggregating finance and AI expertise, starting at JP Morgan in Mid-Cap M&A, pursuing graduate studies in AI at UC Berkeley, and working at Bridgewater Associates.

Element Biosciences Establishes Scientific Advisory Board

Retrieved on:

星期一, 八月 14, 2023

SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the formation of its Scientific Advisory Board with four leading experts on genomics, oncology, chemistry, and biology.

Key Points:

SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the formation of its Scientific Advisory Board with four leading experts on genomics, oncology, chemistry, and biology.
Element's Scientific Advisory Board will provide guidance and direction for research, development, and product innovation as the company continues its success and expansion in the genomics industry.
"With this diverse and accomplished group of scientists from across the globe, our Scientific Advisory Board empowers us to reach new heights in research and product innovation," said Michael Previte, PhD, Element CTO, SVP of R&D, and co-founder.
"I am thrilled to lead Element's Scientific Advisory Board," said Joseph (Jody) Puglisi, Jauch Professor in the Department of Structural Biology at Stanford University School of Medicine and Element's Scientific Advisory Board chair.